Literature DB >> 33766516

Novel insights from fetal and placental phenotyping in 3 mouse models of Down syndrome.

April D Adams1, Victoria Hoffmann2, Laura Koehly3, Faycal Guedj4, Diana W Bianchi5.   

Abstract

BACKGROUND: In human fetuses with Down syndrome, placental pathology, structural anomalies and growth restriction are present. There is currently a significant lack of information regarding the early life span in mouse models of Down syndrome.
OBJECTIVE: The objective of this study was to examine embryonic day 18.5 and placental phenotype in the 3 most common mouse models of Down syndrome (Ts65Dn, Dp(16)1/Yey, Ts1Cje). Based on prenatal and placental phenotyping in 3 mouse models of Down syndrome, we hypothesized that one or more of them would have a similar phenotype to human fetuses with trisomy 21, which would make it the most suitable for in utero treatment studies. STUDY
DESIGN: Here, C57BL6J/6 female mice were mated to Dp(16)1/Yey and Ts1Cje male mice and Ts65Dn female mice to C57BL/B6Eic3Sn.BLiAF1/J male mice. At embryonic day 18.5, dams were euthanized. Embryos and placentas were examined blindly for weight and size. Embryos were characterized as euploid or trisomic, male or female by polymerase chain reaction. A subset of embryos (34 euploid and 34 trisomic) were examined for malformations.
RESULTS: The Ts65Dn mouse model showed the largest differences in fetal growth, brain development, and placental development when comparing euploid and trisomic embryos. For the Dp(16)1/Yey mouse model, genotype did not impact fetal growth, but there were differences in brain and placental development. For the Ts1Cje mouse model, no significant association was found between genotype and fetal growth, brain development, or placental development. Euploid mouse embryos had no congenital anomalies; however, 1 mouse embryo died. Hepatic necrosis was seen in 6 of 12 Dp(16)1/Yey (50%) and 1 of 12 Ts1Cje (8%) mouse embryos; hepatic congestion or inflammation was observed in 3 of 10 Ts65Dn mouse embryos (30%). Renal pelvis dilation was seen in 5 of 12 Dp(16)1/Yey (42%), 5 of 10 Ts65Dn (50%), and 3 of 12 Ts1Cje (25%) mouse embryos. In addition, 1 Ts65Dn mouse embryo and 1 Dp(16)1/Yey mouse embryo had an aortic outflow abnormality. Furthermore, 2 Ts1Cje mouse embryos had ventricular septal defects. Ts65Dn mouse placentas had increased spongiotrophoblast necrosis.
CONCLUSION: Fetal and placental growth showed varying trends across strains. Congenital anomalies were primarily seen in trisomic embryos. The presence of liver abnormalities in all 3 mouse models of Down syndrome (10 of 34 cases) is a novel finding. Renal pelvis dilation was also common (13 of 34 cases). Future research will examine human autopsy material to determine if these findings are relevant to infants with Down syndrome. Differences in placental histology were also observed among strains.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Down syndrome; fetal phenotyping; liver abnormalities; mouse models; placenta

Mesh:

Year:  2021        PMID: 33766516      PMCID: PMC8429205          DOI: 10.1016/j.ajog.2021.03.019

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   10.693


  55 in total

1.  Fetal pyelectasis and Down syndrome: is genetic amniocentesis warranted?

Authors:  J E Corteville; J M Dicke; J P Crane
Journal:  Obstet Gynecol       Date:  1992-05       Impact factor: 7.661

2.  Abnormal prenatal hematological findings in congenital leukemia of Down syndrome with hepatosplenomegaly.

Authors:  Chih-Ping Chen; Shuan-Pei Lin; Tung-Yao Chang; Hsin-Tsung Ho
Journal:  Prenat Diagn       Date:  2007-12       Impact factor: 3.050

3.  Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome.

Authors:  M T Davisson; C Schmidt; E C Akeson
Journal:  Prog Clin Biol Res       Date:  1990

4.  Neonatal hyperammonemia resulting from severe in utero hepatic necrosis.

Authors:  A M Glasgow; S Kapur; M K Miller; S Brudno
Journal:  J Pediatr       Date:  1986-01       Impact factor: 4.406

Review 5.  Trophoblast functions, angiogenesis and remodeling of the maternal vasculature in the placenta.

Authors:  J C Cross; M Hemberger; Y Lu; T Nozaki; K Whiteley; M Masutani; S L Adamson
Journal:  Mol Cell Endocrinol       Date:  2002-02-22       Impact factor: 4.102

6.  Antepartum management and obstetric outcomes among pregnancies with Down syndrome from diagnosis to delivery.

Authors:  Stephanie H Guseh; Sarah E Little; Katherine Bennett; Virginia Silva; Louise E Wilkins-Haug
Journal:  Prenat Diagn       Date:  2017-06-01       Impact factor: 3.050

7.  High expression of platelet-derived growth factor and transforming growth factor-beta 1 in blast cells from patients with Down Syndrome suffering from transient myeloproliferative disorder and organ fibrosis.

Authors:  H Hattori; A Matsuzaki; A Suminoe; K Ihara; H Nakayama; T Hara
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

8.  Increased prevalence of renal and urinary tract anomalies in children with Down syndrome.

Authors:  Juan C Kupferman; Charlotte M Druschel; Gabriel S Kupchik
Journal:  Pediatrics       Date:  2009-09-14       Impact factor: 7.124

9.  Fetal hepatosplenomegaly associated with transient myeloproliferative disorder in trisomy 21.

Authors:  G A Macones; A Johnson; D Tilley; R Wade; R Wapner
Journal:  Fetal Diagn Ther       Date:  1995 Mar-Apr       Impact factor: 2.587

10.  Genetic dissection of Down syndrome-associated congenital heart defects using a new mouse mapping panel.

Authors:  Eva Lana-Elola; Sheona Watson-Scales; Amy Slender; Dorota Gibbins; Alexandrine Martineau; Charlotte Douglas; Timothy Mohun; Elizabeth Mc Fisher; Victor Lj Tybulewicz
Journal:  Elife       Date:  2016-01-14       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.